Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vical Faced With Failure of Another Vaccine Trial

Executive Summary

Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.

Advertisement

Related Content

Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In
Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta
Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Deal Watch: BridgeBio To Launch New Subsidiary Around Rare Disease Candidate Obtained From Alexion
Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash
Genital Herpes: New Therapeutic Approaches Advance
Stumble For Vical/Astellas CMV Vaccine In Kidney Transplants
Vical plummets on placebo promise in herpes study
Vical Shifts To Infectious Disease After Allovectin Fails In Melanoma
GSK discontinues genital herpes vaccine after Phase III failure

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123239

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel